deltatrials
Terminated PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT02698111

Donafenib Monotherapy for Previously Treated Metastatic Nasopharyngeal Carcinoma

Donafenib Monotherapy for Previously Treated Metastatic Nasopharyngeal Carcinoma：an Open-label,Phase 1 Study.

Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Conditions Nasopharyngeal Carcinoma
Interventions Donafenib
Updated 11 times since 2017 Last updated: May 4, 2023 Started: Feb 8, 2017 Primary completion: Oct 20, 2021 Completion: Oct 20, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Corporate policy adjustments

Other terminated trials from Suzhou Zelgen Biopharmaceuticals Co.,Ltd

More terminations from Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Other Nasopharyngeal Carcinoma trials with similar outcome

Browse all Nasopharyngeal Carcinoma trials

A PHASE1/PHASE2 clinical study on Nasopharyngeal Carcinoma, this trial is terminated or withdrawn. The trial is conducted by Suzhou Zelgen Biopharmaceuticals Co.,Ltd and has accumulated 11 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Nov 2017 · 10 months · monthly snapshotNot Yet Recruiting~Nov 2017 – ~Jun 2018 · 7 months · monthly snapshotRecruiting~Jun 2018 – ~Apr 2019 · 10 months · monthly snapshotRecruiting~Apr 2019 – ~Feb 2020 · 10 months · monthly snapshotRecruiting~Feb 2020 – ~Nov 2020 · 9 months · monthly snapshotRecruiting~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshotRecruiting~Jan 2021 – ~Dec 2022 · 23 months · monthly snapshotRecruiting~Dec 2022 – ~Jun 2023 · 6 months · monthly snapshotRecruiting~Jun 2023 – ~Jul 2024 · 13 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 22 months · monthly snapshotTerminated

Change History

11 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Jun 2023 — Jul 2024 [monthly]

    Terminated PHASE1_PHASE2

    Status: Recruiting → Terminated

  4. Dec 2022 — Jun 2023 [monthly]

    Recruiting PHASE1_PHASE2

  5. Jan 2021 — Dec 2022 [monthly]

    Recruiting PHASE1_PHASE2

▶ Show 6 earlier versions

  1. Nov 2020 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

  2. Feb 2020 — Nov 2020 [monthly]

    Recruiting PHASE1_PHASE2

  3. Apr 2019 — Feb 2020 [monthly]

    Recruiting PHASE1_PHASE2

  4. Jun 2018 — Apr 2019 [monthly]

    Recruiting PHASE1_PHASE2

  5. Nov 2017 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting · Phase: PHASE1 → PHASE1_PHASE2

  6. Jan 2017 — Nov 2017 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Data source: Suzhou Zelgen Biopharmaceuticals Co.,Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations